Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Bladder cocktail aims to stop recurrent UTIs in spinal cord injury

NCT ID NCT07643974

Disease control Sponsor: Medstar Health Research Institute Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Aug 21, 2026 · Updated 4 times

Summary

This early study tests whether washing the bladder with an antibiotic (gentamicin) followed by a probiotic (Lactobacillus) can help restore healthy bacteria and prevent urinary tract infections in people with neurogenic bladder due to spinal cord injury, multiple sclerosis, or spina bifida. 48 adults will receive six bladder washes over two weeks, with timing varied to see which schedule works best. The goal is to see if the probiotic can re-colonize the bladder and keep infections away for up to 28 days.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Gentamicin and Lactobacillus rhamnosus GG (LGG) bladder washes
What this could lead to
If successful, this could point toward a way to reduce frequent urinary tract infections in people with neurogenic bladder, potentially lowering antibiotic use.
What could go wrong
This is a very early Phase 1 trial with only 48 participants, so results may not apply broadly. The approach involves bladder washes, which may be uncomfortable or cause irritation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Early phase 1

The earliest testing in people: a first look at safety, in a very small group.

Participants

About 48 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Aug 2026

An estimate. Start dates often move.

Expected to finish

Sep 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Neurologic diagnosis * ≥18 years old * Neurogenic bladder for at least 6 months * No USQNB-IC A, B1, or B2 symptoms * No currently diagnosed UTI (within 24 hours of initiating instillations) * Community dwelling (not in acute hospital setting) Exclusion Criteria: * Known genitourinary pathology beyond NLUTD (i.e. kidney stones, bladder stones, vesicoureteral reflux, etc.) * Use of prophylactic antibiotics or any antibiotics within 2 weeks of beginning instillations * Instillation of intravesical agents other than saline bladder wash * Immunodeficiency * Psychologic or psychiatric conditions influencing the ability to follow instructions * Allergy to ampicillin, daptomycin, gentamicin/gentamycin, or probiotics * Participation in another study which could confound results

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Multiple sclerosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

multiple sclerosis spina bifida spinal cord disorder spinal cord injury Urinary Bladder, Neurogenic urinary tract infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Multiple sclerosis Neurogenic bladder (NB) Neurogenic lower urinary tract dysfunction Spina bifida Spinal cord injury Urinary tract infection(UTI)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • MedStar National Rehabilitation Hospital

    Washington D.C., District of Columbia, 20010, United States

  • University of Pittsburgh Medical Center

    Pittsburgh, Pennsylvania, 15224, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.